Patent ID: 7932026
Filing Date: 2011-04-26
Classification: A61K,A61P,C12Q,G01N

Abstract:
1. A method for determining whether a colorectal tumor in a human subject is responsive to treatment with cetuximab or panitumumab, comprising (i) assaying for the presence of a wild-type KRAS gene encoding a glycine residue at codon 12 and 13 in a sample of said tumor or for the presence of a mutated KRAS gene in a sample of said tumor, wherein said mutated KRAS gene encodes a G12C; G12A; G12D; G12R; G12S; G12V; or G13C mutation and (ii) identifying the tumor in the human subject as responsive to treatment with cetuximab or panitumumab when the wild-type KRAS gene is present, or identifying the tumor in a human subject as not responsive to treatment with cetuximab or panitumumab when said mutated KRAS gene is present.